RenovoRx

RenovoRx announces acceptance of three abstracts at ASCO GI 2025, SIO 2025, and SSO 2025, supporting its TAMP therapy platform with human PK and pre-clinical data. The Phase III TIGeR-PaC trial, evaluating a novel drug-device combination for pancreatic cancer, expects patient enrollment and interim analysis completion by mid-2025.

The Phase III TIGeR-PaC trial evaluates intra-arterial gemcitabine via RenovoCath for locally advanced pancreatic cancer, aiming for improved survival and reduced toxicity. Interim analysis supports study continuation, with final results expected by 2025. RenovoRx's TAMP technology targets precise drug delivery to tumors.

RenovoRx's TAMP therapy platform delivers precise treatment across arterial walls near tumors, aiming to reduce toxicity and improve efficacy. Its Phase III product combines a novel oncology drug with the RenovoCath® device, currently under FDA investigation for LAPC treatment. RenovoRx is exploring further commercialization of TAMP and RenovoCath.

Recent cancer treatment advancements include a stage 4 breast cancer patient achieving complete remission through immunotherapy and a Scottish woman receiving a personalized mRNA cancer vaccine. Key players in these advancements include Oncolytics Biotech Inc., Cargo Therapeutics, Inc., Immuneering Corporation, RenovoRx, Inc., and Repare Therapeutics Inc. Oncolytics Biotech highlights 2024 achievements and prepares for 2025 with promising breast and GI cancer data.

RenovoRx's Phase III TIGeR-PaC trial, evaluating TAMP™ therapy for locally advanced pancreatic cancer, is enrolling patients at SCRI Oncology Partners. Dr. Meredith Pelster leads the study, aiming to improve survival and reduce side effects compared to standard care.

RenovoRx initiates patient enrollment at SCRI Oncology Partners for Phase III TIGeR-PaC trial in locally advanced pancreatic cancer, evaluating TAMP therapy platform. Dr. Meredith Pelster appointed as Principal Investigator. Enrollment expected to complete in H1 2025.

RenovoRx, Inc. announces SCRI Oncology Partners' enrollment in the Phase III TIGeR-PaC clinical trial evaluating the TAMP™ therapy platform for locally advanced pancreatic cancer. Dr. Meredith Pelster leads the study, aiming to offer improved survival and reduced side effects compared to standard care.

RenovoRx (RNXT) enrolls patients with LAPC in Phase III TIGeR-PaC trial at SCRI Oncology Partners, using TAMP therapy to deliver gemcitabine, comparing it to standard care.

RenovoRx CEO Shaun Bagai will host an investor fireside chat on Dec 17, 2024, discussing 2024 achievements and 2025 outlook, focusing on RenovoCath's commercialization strategy and updates on the Phase III TIGeR-PaC trial for locally advanced pancreatic cancer treatment. Key 2025 milestones include the second interim data readout and patient enrollment completion.

Northwell Health Cancer Institute joins TIGeR-PaC study evaluating RenovoRx's TAMP therapy for locally advanced pancreatic cancer, aiming for full enrollment by mid-2025.